

1 **BA.1 and BA.2 sub-lineages of Omicron variant have comparable replication**
2 **kinetics and susceptibility to neutralization by antibodies**

3 **Running title:** Replication kinetics of SARS-CoV-2 variants

4 Janmejay Singh^{1*}, Aleksha Panwar^{1*}, Anbalagan Anantharaj^{1*}, Chitra Rani¹, Monika
5 Bhardwaj¹, Parveen Kumar¹, Kamal Pargai¹, Partha Chattopadhyay^{2,3}, Priti Devi^{2,3},
6 Ranjeet Maurya^{2,3}, Pallavi Mishra², Anil Kumar Pandey⁴, Rajesh Pandey² and
7 Guruprasad R. Medigeshi^{1#}

8 1. Bioassay Laboratory and Clinical and Cellular Virology Laboratory, Translational
9 Health Science and Technology Institute, Faridabad, Haryana. INDIA.

10 2: INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) laboratory, CSIR-Institute
11 of Genomics and Integrative Biology, Delhi, INDIA.

12 3: Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India.

13 4: Employees State Insurance Corporation Medical College and Hospital, Faridabad,
14 Haryana, INDIA.

15 *** These authors contributed equally**

16 **# Corresponding author:**

17 Guruprasad R. Medigeshi, PhD

18 Translational Health Science and Technology Institute,

19 NCR-Biotech Science Cluster,

20 P.O. Box # 4, Faridabad-Gurugram Highway,

21 Faridabad 121001. INDIA.

22 Tel: +91-0129-2876311.

23 Email: gmedigeshi@thsti.res.in

24 **ABSTRACT**

25 The Omicron variant of SARS-CoV-2 is capable of infecting unvaccinated, vaccinated
26 and previously-infected individuals due to its ability to evade neutralization by
27 antibodies. With three sub-lineages of Omicron emerging in the last four months, there
28 is inadequate information on the quantitative antibody response generated upon natural
29 infection with Omicron variant and whether these antibodies offer cross-protection
30 against other sub-lineages of Omicron variant. In this study, we characterized the
31 growth kinetics of Kappa, Delta and Omicron variants of SARS-CoV-2 in Calu-3 cells.
32 Relatively higher amounts infectious virus titers, cytopathic effect and disruption of
33 epithelial barrier functions was observed with Delta variant whereas infection with
34 Omicron variant led to a more robust induction of interferon pathway, lower level of virus
35 replication and mild effect on epithelial barrier. The replication kinetics of BA.1 and BA.2
36 sub-lineages of the Omicron variant were comparable in cell culture and natural
37 Omicron infection in a subset of individuals led to a significant increase in binding and
38 neutralizing antibodies to both BA.1 and BA.2 sub-lineages but these levels were lower
39 than that produced against the Delta variant. Finally, we show that Cu^{2+} , Zn^{2+} and Fe^{2+}
40 salts inhibited *in vitro* RdRp activity but only Cu^{2+} and Fe^{2+} inhibited both the Delta and
41 Omicron variants in cell culture. Thus, our results suggest that high levels of interferons
42 induced upon infection with Omicron variant may counter virus replication and spread.
43 Waning neutralizing antibody titers rendered subjects susceptible to infection by
44 Omicron variant and natural Omicron infection elicits neutralizing antibodies that can
45 cross-react with other sub-lineages of Omicron and other variants of concern.

46 **KEYWORDS:** SARS-CoV-2; COVID-19; Delta variant; Omicron; RdRp; Copper; Iron

47 INTRODUCTION

48 Close to 17 million cases of COVID-19 was reported from India during the second wave
49 of SARS-CoV-2 from March 2021 to June 2021 overwhelming the public health
50 infrastructure resulting in close to 40% of the >500,000 deaths that has occurred in this
51 pandemic. The surge was due to novel SARS-CoV-2 variant from the lineage B.1.617.2
52 (Delta variant) which was shown to be more virulent with shorter incubation periods and
53 ability to cause severe disease([1-4](#)). Many reports have shown that the neutralizing
54 antibodies from prior infection or that elicited by some of the licensed COVID-19
55 vaccines show a decrease in the efficiency to neutralize the Delta variant thereby
56 compromising vaccine efficacy against this variant([5-7](#)). Delta variant was the major
57 circulating SARS-CoV-2 variant until the emergence of B.1.1.529 (Omicron) variant in
58 November 2021 which has now replaced the Delta variant in most of the countries. The
59 ongoing third wave of SARS-CoV-2 infections, which is on the decline and attributed to
60 the Omicron variant of SARS-CoV-2, has resulted in milder symptoms and lower
61 hospitalizations. In addition to the less virulent Omicron variant, increased vaccination
62 coverage and hybrid immunity may have contributed to reduced impact of third wave in
63 India. Three sub-lineages of Omicron (BA.1, BA.2 and BA.3) have emerged and are
64 currently circulating in India and other parts of the world([8](#)). The success of Omicron
65 variant and its sub-lineages in driving the current phase of the pandemic has been
66 attributed to a large number of mutations leading to escape from neutralizing antibodies
67 generated by prior infection or vaccination([9-12](#)). Recent reports suggest that the
68 antibody response between the sub-lineages may not be significantly different and

69 exposure to one of the sub-lineages offers cross-protection against other members of
70 Omicron sub-lineage and also against past variants([13](#), [14](#)).

71

72 In addition to evading humoral immunity, data from animal models suggest that the
73 success of SARS-CoV-2 variants of concern (VoCs) in driving new waves of infection
74 can be attributed to multiple factors such as increased virulence, enhanced
75 transmission, altered pathogenicity and replication fitness([15-20](#)). Therefore, efforts to
76 characterize and understand the replication kinetics of circulating VoCs would provide
77 information on virulence mechanisms, immune evasion properties and augment our
78 ability to develop therapeutic strategies. In this study, we compared the replication
79 kinetics of some of the SARS-CoV-2 VoCs namely, the Kappa and Delta variants and
80 BA.1 and BA.2 sub-lineages of Omicron variant in human lung epithelial
81 adenocarcinoma (Calu-3) cells grown on transwells and also in air-liquid interface
82 models. We monitored the interferon response and its downstream effectors in infected
83 cells and tested the effect of divalent cations on virus infection and RNA-dependent
84 RNA polymerase (RdRp) activity. We show that both binding and neutralizing antibodies
85 wane by >50% in six months in a cohort of participants with hybrid immunity. Natural
86 exposure to the Omicron variant led to a significant increase in binding and neutralizing
87 antibodies to BA.1 and BA.2 sub-lineages of Omicron. The levels of neutralizing
88 antibodies were higher against the Delta variant as compared to the Omicron sub-
89 lineages. These data suggest that Omicron infection elicits neutralizing antibodies that
90 can cross-react with other sub-lineages of Omicron and other VoCs in people with
91 hybrid immunity. Our results provide clues to the relative replication fitness of these

92 VoCs and their ability to induce interferon responses and susceptibility to divalent
93 cations and may help to develop novel strategies to counter viral replication.

94

95 **RESULTS**

96 **Peak COVID-19 positivity in second wave coincides with high viral load**

97 A total of 117,434 NP/OP swab samples were tested for COVID-19 by RT-PCR at the
98 bioassay laboratory of the institute from April 2020 to July 2021. Peak positivity in the
99 year 2020 was observed in the months of June-July with 15% positivity during these
100 months (Supplementary Fig. S1A(i)). Previous reports have identified B.6 lineage as
101 one of the predominant lineages during this period circulating in India ([21](#), [22](#)). We have
102 isolated few clinical isolates from B.6 lineage as reported earlier and plaque-purified one
103 of the isolates which was used in this study as a representative of ancestral virus isolate
104 ([23](#)). The number of positive cases was around 10% of the total samples tested until
105 November 2020 and dropped drastically to around 0.1% of the total tested samples in
106 the month of February 2021 (Supplementary Fig. S1A(ii)). Although only 8 of the 8012
107 tested samples were RT-PCR positive in February 2021, 4 of these 8 samples had RT-
108 PCR cycle threshold (Ct) values <20 and 2 with Ct values between 20-25. RT-PCR
109 positivity jumped to 1.1% (85 out of 7558) in March with over 50% of the positive
110 samples having Ct values of <25 clearly indicating a large number of infections with a
111 high viral load during February and March 2021 (Supplementary Fig. S1B). The
112 following months of April and May saw a sudden spike in the peak positivity rate which
113 increased to 27.7% and 24.5% which is now termed as the "second wave" and the
114 SARS-CoV-2 variants from B.1.617.1/2 (Kappa/Delta) lineages have been attributed to

115 this sudden spike which overwhelmed the healthcare infrastructure leading to large
116 scale mortality ([24](#)). 40% of the NP/OP samples tested in April 2021 had Ct values of
117 less than 25 which reduced to 28% of the total samples in May indicating a high viral
118 burden in patients during this period resulting in increased transmission of the virus
119 among the contacts.

120

121 **Disruption of cellular junctions by SARS-CoV-2 Delta and Kappa variants**

122 We were able to isolate the B.1.617.1 (Kappa) and B.1.617.2 (Delta) variants from
123 clinical samples and got the virus stocks verified by whole genome sequencing. We
124 measured the growth kinetics of these two variants in comparison with the B.6 lineage
125 virus. Calu-3 cells were infected with 0.01 MOI of SARS-CoV-2 from lineages B.6,
126 B.1.617.1 and B.1.617.2 respectively. We estimated viral titers in the supernatants at 24
127 and 48 h pi by plaque assay. Total RNA was isolated from cells at each time point for
128 measuring copy numbers of N gene by quantitative RT-PCR. We observed a
129 significantly higher viral titers with B.1.617.2 variant relative to B.6 lineage virus at 24 h
130 pi. The virus titers at 48 h pi was reduced in both the Kappa and the Delta variant
131 samples most probably due to the increased cytopathic effect at this time point (Fig.
132 1A). However, no difference in N gene RNA copy numbers were detected between the
133 three isolates by RT-PCR at either of the time-points (Fig. 1B). As SARS-CoV-2 was
134 shown to disrupt tight junctions in Calu-3 and human airway epithelial cells ([23](#), [25](#)), we
135 further assessed the effect of infection of B.6 and B.1.617.1 and B.1.617.2 variants on
136 cellular junctions of polarized Calu-3 cells. Cells were grown on transwell culture inserts
137 for 21 days to allow for polarization into apical and basolateral surface and formation of

138 permeability barrier as measured by the trans-epithelial electrical resistance (TEER).
139 Polarized Calu-3 cells were infected with 0.3 MOI of each of the three virus isolates and
140 the TEER was monitored for 48 hours. Cells that were either mock-infected or infected
141 with B.6 lineage virus showed no significant change in TEER up to 48 h (Fig. 1C).
142 Epithelial barrier function was disrupted by 48 h in cells infected with either the Kappa
143 (B.1.617.1) or the Delta (B.1.617.2) variants. However, a significant decline in the TEER
144 values was observed for the Delta variant (Fig.1C). Surprisingly, the virus titers in either
145 the apical or basolateral chambers were not significantly different between the three
146 isolates (Fig. 1D) at 48 h pi suggesting that the increasing cytopathogenicity by the
147 Delta variant may be responsible for significantly higher disruption of lung epithelial
148 barrier functions. These findings were further corroborated by confocal microscopy
149 where transwell culture inserts were fixed at 48 h pi and stained with antibodies against
150 SARS-CoV-2 nucleocapsid (N) protein, occludin (marker for tight junction) and β -
151 catenin (marker for adherens junction) (Fig. 2). The staining pattern of both occludin and
152 β -catenin was comparable between mock- and B.6-infected cells. However, the same
153 was perturbed in both the Kappa and the Delta variant infected cells and disruption of
154 occludin staining appeared to be more drastic in cells infected with the Delta variant
155 compared to the Kappa variant (Fig. 2). Our results suggest that the Delta variant
156 infection has relatively more deleterious effects on epithelial cell functions most
157 probably due to increased fusogenic functions leading to syncytia formation and cell
158 death([19](#)).

159

160 **Infection with Omicron variant generates lower levels of infectious virus**

161 Delta variant was reported to have higher transmissibility and pathogenicity in humans
162 and animal models([19](#), [26-28](#)) whereas Omicron variant showed attenuated growth([17](#),
163 [29](#)). We performed growth curve analysis of SARS-CoV-2 viruses from the lineages B.6
164 (isolate from 2020), B.1.617.2 (Delta) and B.1.1.529 (Omicron) in Calu-3 cells by
165 infecting cells with 0.3 MOI and estimating viral genome equivalents (N gene) by qRT-
166 PCR from infected cells and virus titers from culture supernatants by plaque assays at
167 indicated time-points (Fig. 3). We found that viral RNA replication peaked by 24 h pi for
168 both the B.6 and the Delta variants and both these isolates had comparable viral N-
169 gene levels by qRT-PCR at all the time points. However, the same for Omicron variant
170 was about 70% lower as compared to the other two lineages at all the time-points (Fig.
171 3A). Similarly, viral titers in the supernatant increased from 12 h pi to 24 h pi and the
172 levels were maintained at 36 h pi in the case of B.6 lineage virus. However, consistent
173 with the sub-genomic N RNA levels, the viral titers for the Omicron variant was
174 significantly lower compared to both B.6 and the Delta variant at all the time points (Fig.
175 3B) which is in agreement with recent reports([30](#), [31](#)). These observations were further
176 corroborated by western blot analysis performed with cell lysates prepared from infected
177 cells collected in lysis buffer at 12 and 24 h pi where the N protein was consistently
178 lower at both 12 and 24 h pi in cells infected with Omicron as compared to B.6 and
179 Delta infection (Fig. 3C). To further verify whether the lower titers observed in the
180 Omicron infection is due to compromised viral entry, we performed viral entry
181 experiments by infecting cells with 5 MOI for one hour and estimated the amount of
182 internalized RNA by qRT-PCR. We found that, contrary to reduced viral titers and viral
183 RNA levels in Omicron infection, the intracellular viral RNA levels were higher as

184 compared to B.6 and the Delta variant suggesting that the reduced viral titers and viral
185 RNA levels is not due to compromised viral entry into these cells (Fig. 3D).

186

187 **Interferon-dependent responses and reduced barrier disruption by Omicron** 188 **variant**

189 Innate immune responses mediated by interferons act as the first line of defence
190 against viral infections and SARS-CoV-2 was found to be less capable of evading the
191 interferon response compared to SARS-CoV-1(32) (33). Additionally, interferon induction
192 coincided with viral clearance in young adults with mild SARS-CoV-2 infection
193 suggesting a crucial role for antiviral response in resolving infection(34). We tested the
194 induction of interferon-dependent antiviral response genes in cells infected with B.6,
195 Delta and Omicron lineages. Total RNA isolated from Calu-3 cells after indicated time-
196 points post-infection were used to estimate the transcript levels of interferon pathway
197 genes by RT-qPCR (Fig. 4). We found that infection with Omicron variant led to
198 significantly higher induction of interferon- β (Fig. 4A) and the epithelial cell specific
199 interferon- λ 1 (Fig. 4B) and the downstream effectors of interferon pathway namely,
200 interferon-stimulated gene 15 (ISG15) (Fig. 4C) and 2'-5'-oligoadenylate synthetase 1
201 (OAS1) (Fig. 4D) at all the time-points tested suggesting that SARS-CoV-2 ancestral
202 virus (B.6) and both the variants induce innate immune responses and lower levels of
203 titers observed in the Omicron infected cells is due to robust induction of interferon
204 pathway which is in agreement with previous reports(35). To further confirm that the
205 lower levels of replication and infection by Omicron variant translates to compromised
206 ability to disrupt the epithelial barrier functions, we compared the effect of Delta and

207 Omicron variant infection in an air-liquid culture model using Calu-3 cells. Cells were
208 cultured on transwells at the air-liquid interface and infected with respective virus strains
209 at 0.3 MOI. Trans-epithelial electrical resistance was monitored for 36 h (Fig. 5A). We
210 observed a gradual insignificant decline in the TEER values after 12 h pi in cells
211 infected with the Omicron variant and, by 36 h pi, barrier integrity was compromised by
212 50% relative to mock-infected cells. However, infection with Delta variant led to drastic
213 reduction of >80% in TEER values after 24 h pi suggesting rapid induction of cell death
214 and disruption of epithelial barrier (Fig. 5A). We measured viral titers in the basolateral
215 chamber and, surprisingly, the viral titers were comparable between the Omicron and
216 Delta variant suggesting comparable transcytosis of both these variants but significantly
217 higher cytopathic effect of the Delta variant as compared to the Omicron variant (Fig.
218 5B). Disruption of cellular junctions was further confirmed by staining the cells with
219 antibodies against SARS-CoV-2 N, occludin and β -catenin. As expected from the TEER
220 values, infection with the Delta variant showed large syncytia formation as visualized by
221 N-positive cells and disruption of and reduction in occludin and β -catenin staining (Fig.
222 5C). Cells infected with the Omicron variant showed fewer infected cells, mild
223 perturbation in junction proteins (Fig. 5C) further confirming the milder effect of this
224 variant on epithelial barrier functions and pathogenicity as observed in animal studies by
225 other groups([17](#), [29](#)).

226

227 **Comparable replication kinetics and neutralization of BA.1 and BA.2 sub-lineages**

228 Three sub-lineages of Omicron have been identified so far([8](#), [36](#)) and BA.1 and BA.2
229 sub-lineages are the circulating virus strains in the third wave in India since November

230 2021 (Supplementary Fig. S2). We isolated both BA.1 and BA.2 sub-lineage viruses
231 from patient samples and performed growth curve analysis of both these sub-lineages
232 as described earlier in Calu-3 cells. We found no difference in the cellular viral RNA
233 levels and viral titers in the supernatants at the indicated time-points post-infection (Fig.
234 6A and 6B). To further verify the potential of antibodies from vaccinated individuals to
235 neutralize both BA.1 and BA.2 lineages, we enrolled 15 subjects (Median age 29; 5
236 Female, 10 Male) who were vaccinated with ChAdOx1 nCoV-19 vaccine in May 2021.
237 We collected samples at three time points: i) first sample at one month after complete
238 vaccination (June 2021), ii) a follow-up sample after 6 months (Dec 2021) and iii) a third
239 sample during the ongoing third wave of SARS-CoV-2 infection (Feb 2022). We
240 performed quantitative nucleocapsid (N) and RBD ELISA([13](#)) to monitor antibody levels
241 in samples from the three bleeds. Six of the 15 samples had detectable levels of N
242 antibodies (cut off: 15 BAU/mL) post-vaccination suggesting that these subjects had
243 hybrid immunity (infection + vaccination) as the ChAdOx1 nCoV-19 vaccine does not
244 generate N antibodies. The geometric mean titer (GMT) of N-ELISA antibodies reduced
245 from 14.0 (95% CI: 8.4, 23.1) in June 2021 to 11.5 (95% CI: 7.9, 16.6) in Dec 2021 with
246 only five positive samples. However, the samples collected during the Omicron surge in
247 Feb 2022 showed a significant increase in N antibodies with a GMT of 53.5 (95% CI:
248 19.6, 145.8) with ten positive samples (Fig. 6C). Similar trends were observed with RBD
249 antibodies where we observed an approximate 3-fold in the GMT of RBD antibodies
250 from 266.0 (95% CI: 120.2, 368.1) in June 2021 to 76.5 (95% CI: 36.7, 159.5) in Dec
251 2021. The samples from Omicron wave showed a spike in RBD antibody titers to 935.3
252 (95% CI: 440.4, 1986) (Fig. 6D).

253 To establish virus neutralization titer assays for the Omicron variant, we first
254 performed conventional plaque assays with the virus stocks using both Calu-3 and Vero
255 E6 cells and found delayed and small plaque formation in Calu-3 cells as compared to
256 the Delta variant (Supplementary Fig. S3A). However, unlike the Delta variant, the
257 Omicron variant did not produce plaques up to 48 h post-infection in Vero E6 cells. As
258 Calu-3 cells are slow-growing and plaque assays are not amenable for high-throughput
259 neutralization assays, we first tested the ability of the Omicron variant to form infectious
260 foci by antibody staining with anti-spike and anti-nucleocapsid antibodies in Vero E6
261 cells. While the Delta variant formed clear discernable infectious foci with both the
262 antibodies, the same was less distinct with anti-spike antibodies for the Omicron variant
263 although it was countable by the spot reader (Supplementary Fig. S3B). Staining with
264 nucleocapsid antibodies produced better foci in the case of Omicron variant but the
265 quality of foci was not comparable with the Delta variant (Supplementary Fig. S3B). We
266 next tested secondary antibodies conjugated with fluorescent dye instead of
267 horseradish peroxidase enzyme (HRP) and visualized the infectious foci in fluorescence
268 mode. Use of fluorescence-based detection was far superior to HRP-based enzyme-
269 substrate detection for the Omicron variant (Supplementary Fig. S3C). The assay
270 showed consistency in performance as measured by the antibody titers of an in-house
271 pooled convalescent reference serum (Supplementary Fig. S3D). We adopted this
272 method for comparing the neutralizing antibody titers against the Delta and Omicron
273 variants. The neutralizing antibody titers for Delta variant as measured by FRNT assay
274 also showed about three-fold reduction from a GMT of 257.5 (95% CI: 145.8, 454.7) in
275 June 2021 to 87.5 (49.7, 154.1) in Dec 2021 (Fig.6E). However, as expected from the

276 ELISA titers, the GMT of neutralizing antibodies increased significantly to 914.0 (95%
277 CI: 468.7, 1782) in samples from the third wave in Feb 2022 indicating re-infection in
278 most of these individuals. As shown by us and others([10](#), [37](#)), the neutralizing antibody
279 titers for Omicron variant was drastically reduced at all the time points relative to that of
280 Delta variant (Fig. 6F). Nine out of 15 samples had FRNT₅₀ value above the level of
281 detection after vaccination in June 2021. The GMT of neutralizing antibodies for the
282 Omicron variant was 26.9 (95% CI: 15.6, 46.4) in these samples. The number of
283 samples positive for Omicron antibodies reduced to six out of 15 bringing the down the
284 GMT of neutralizing antibodies to 18.3 (95% CI: 11.6, 28.7) by Dec 2021. As expected,
285 the surge in Omicron infections in the study area was reflected in the GMT of
286 neutralizing antibodies in samples from Feb 2022 (Fig. 6F). Surprisingly, the samples
287 from Omicron surge showed relatively lower titer, a GMT of 261.9 (95% CI: 113.0,
288 607.5) as compared to a GMT of 914.0 (95% CI: 468.7, 1782) for the Delta variant
289 suggesting that natural infection with Omicron variant generates significantly higher
290 levels of antibodies to the Delta variant.

291 SARS-CoV-2 sequencing data from the National Capital Region (NCR), our
292 study site, showed co-occurrence of B.1.617.2 (Delta) and various AY.* (Delta plus)
293 lineages during the months of September 2021 to December 2021, wherein all AY
294 lineages were more in circulation than the parent B.1.617.2 lineage (Supplementary
295 Figure S2). It is important to note that a rise in the cases of Omicron lineages (B.1.529,
296 BA.1 and BA.2) is observed from December 2021 onwards. This is concomitant with the
297 arrival of Omicron variant in India and a gradual decrease in circulation of Delta lineage.
298 Delta variant was superseded by Omicron by January 2022. Within Omicron lineages,

299 cases of BA.2 sub-lineage increased/spread at a faster rate compared to other Omicron
300 lineages (BA.1 and B.1.529) (Supplementary Figure S2) which is similar to reports from
301 other countries. This is consistent with the observations that BA.2 lineage has increased
302 rates of transmission ([38](#), [39](#)). We enrolled participants (n=19) who were either COVID-
303 19 RT-PCR positive in the ongoing Omicron surge or had symptomatic respiratory
304 infection but got no COVID-19 testing done. The GMT of neutralizing antibodies for
305 BA.1 and BA.2 sub-lineages in these samples were 538.1 (95% CI: 338.5, 855.3) and
306 910.6 (95% CI: 608.2, 1363) and this difference was not statistically significant as
307 reported by others([40](#)). As we recently reported minimal to no neutralizing antibodies
308 against the Omicron variant in subjects with vaccine-induced or hybrid immunity at the
309 beginning of the surge in COVID-19 cases in December 2021([12](#)), our data suggests
310 that enhanced neutralizing antibody titers observed in this study cohort is due to natural
311 exposure to SARS-CoV-2 Omicron variant.

312

313 **Copper and Iron (II) salts inhibit both Delta and Omicron variant infection**

314 Divalent cations play an important role in replication of RNA viruses([41](#)) and previous
315 reports have suggested inhibition of coronavirus replication by Zn salts([42](#)). We
316 established the fluorescence-based SARS-CoV-2 RNA-dependent RNA polymerase
317 (RdRp) assay using purified nsp7, nsp8 and nsp12 proteins with minor modifications
318 based on previous reports([43-45](#)). RdRp assays were performed in the presence of 10
319 μM , 100 μM or 1000 μM of $\text{CaCl}_2/\text{CuCl}_2/\text{FeSO}_4/\text{ZnSO}_4$. CaCl_2 did not affect RdRp
320 activity under these conditions. At 1000 μM , CuCl_2 showed about 35% reduction in
321 RdRp activity while FeSO_4 and ZnSO_4 showed 85% and 60% inhibition respectively at

322 the same concentration (Fig. 7A). At 100 μM , FeSO_4 showed 25% reduction in activity
323 which was significant compared to untreated while ZnSO_4 showed 52% inhibition at this
324 concentration (Fig. 7A). Only ZnSO_4 was capable of inhibiting SARS-CoV-2 RdRp
325 activity albeit by only 22% at 10 μM (Fig. 7A). The 50% inhibitory concentration (IC_{50}) of
326 ZnSO_4 and FeSO_4 in RdRp assays was 313 μM and 347 μM respectively (Fig. 7B and
327 7C). To further confirm the validity of these *in vitro* inhibition in cell culture, we infected
328 Calu-3 cells with either the Delta variant or the Omicron variant and medium
329 supplemented with 50 μM each of $\text{CaCl}_2/\text{CuCl}_2/\text{FeSO}_4/\text{MnCl}_2/\text{ZnSO}_4$ was added after
330 virus adsorption and cells were cultured for 24 h. This concentration of salts was shown
331 to not affect viability of the cells (Supplementary Figure S4). Virus titers in the infected
332 culture supernatants were estimated by plaque assays. Contrary to RdRp assay results,
333 ZnSO_4 at 50 μM concentrations failed to show any inhibition of either the Delta or the
334 Omicron variants in Calu-3 cells (Fig. 7D and 7E). Similarly, neither CaCl_2 nor MnCl_2
335 had any impact on virus titers. However, both CuCl_2 and FeSO_4 showed significant
336 inhibition of virus titers. Both these salts inhibited the Delta variant infection by 70%
337 (Fig. 7D) and the effect was even more drastic (>90% inhibition) in the case of Omicron
338 variant (Fig. 7E). Therefore, our results suggest that copper and iron salts may have
339 both direct and indirect antiviral activity against SARS-CoV-2 when added post-
340 infection.

341

342 **DISCUSSION**

343 SARS-CoV-2 Delta variant was shown to be more infectious and duration from PCR
344 positivity or symptoms with this variant was shorter as compared to other SARS-CoV-2

345 virus strains leading to faster transmission and severe disease. In our study, the Delta
346 variant showed enhanced disruption of epithelial barriers and junction proteins
347 suggesting that the enhanced cytopathic effect and syncytia formation combined with
348 the ability to escape from neutralizing antibodies has provided a growth advantage for
349 Delta variant([1](#), [2](#), [28](#)). Contrary to the enhanced pathogenicity of the Delta variant, the
350 Omicron variant showed lower replication and had milder effect on epithelial barrier
351 functions which correlates with less number of severe cases, hospitalization and lower
352 number of deaths due to COVID-19 in the ongoing third wave of SARS-CoV-2 infections
353 in India which is similar to what has been reported from other countries([46](#)). The clinical
354 samples for this study was collected during the second and third wave of COVID-19 in
355 India during which the Delta and Omicron variants were the predominant circulating
356 virus strains. Cohort data of patients with mild COVID-19 infection has shown that RBD
357 antibodies decay with a half-life of 69 days([47](#)). We observed a three-fold reduction in
358 RBD antibody and neutralizing antibody titers after six months. However, most of the
359 samples had no neutralizing antibodies against the Omicron variant after six months of
360 vaccination suggesting that waning neutralizing titers are an important determinant of
361 reinfections and may also contribute to increased susceptibility to new variants of
362 concern that escape pre-existing humoral immunity. The high-throughput neutralizing
363 antibody assay we established in this study enabled us to circumvent the challenges of
364 estimating neutralizing antibody titers for the Omicron variant as it grew poorly and did
365 not form distinct plaques or infectious foci like the Delta variant. Currently, BA.1 and
366 BA.2 sub-lineages of the Omicron variant are circulating in India and reports have
367 raised concern about the enhanced pathogenicity or transmissibility of BA.2 sub-lineage

368 due to unique mutations in the spike region(39, 48). We show that both BA.1 and BA.2
369 sub-lineages of Omicron variant have comparable replication kinetics in Calu-3 cells.
370 Our sequencing data suggests that the BA.2 sub-lineage of the Omicron variant was the
371 predominant circulating virus at the time of the study and relatively higher levels of
372 neutralizing antibodies to BA.2 was observed in study participants as compared to BA.1
373 further confirming that BA.2 may have been the infecting virus. We show that
374 participants who were naturally infected with the Omicron variant generated neutralizing
375 antibodies against both BA.1 and BA.2 sub-lineages indicating that exposure to any of
376 the sub-lineages of Omicron would confer cross-protection against other members of
377 the sub-lineage in agreement with other reports(14, 40). Interestingly, higher titers of
378 neutralizing antibodies were observed against the Delta variant which was no longer in
379 circulation indicating a broader cross-protective immune response most likely due to
380 conserved B-cell and T-cell epitopes in the Omicron variant that could have triggered
381 the memory responses in people with hybrid immunity(49, 50). Thus, natural infection
382 with Omicron variant may have acted as a booster eliciting cross-reacting antibodies
383 across Omicron sub-lineages and other VoCs in young adults.

384

385 Several studies have reported that interferons expressed in the lower respiratory tract
386 contribute to tissue damage, impair regeneration of lung epithelium and contribute to
387 morbidity observed in COVID-19 patients(51, 52). We observed similar levels of
388 induction of *IFN-β* and *IFN-λ1* and the downstream effectors namely *ISG15* and *OAS1*
389 in cells infected with the Delta variant and with the ancestral B.6 lineage virus
390 suggesting that suppression of innate immune responses is not a contributory factor in

391 increased pathogenesis observed with the Delta variant. Despite lower levels of
392 infection, the Omicron variant induced higher levels of interferon pathway genes. Since
393 the Omicron variant was shown to mostly replicate in the upper respiratory tract([53](#), [54](#)),
394 this suggests that interferon-dependent antiviral responses may limit viral replication
395 and further tissue spread thus resulting in milder symptoms and resolution of infection.
396 Therefore, interferon therapy targeted towards the upper respiratory tract may be more
397 effective in the case of infection with the Omicron variant. In addition to interferons, our
398 results suggest that supplementation with copper and iron salts may also augment the
399 antiviral strategy for SARS-CoV-2 as both CuCl_2 and FeSO_4 inhibited both the Delta and
400 Omicron variants in Calu-3 cells.

401
402 Vaccines have played a major role in bringing the COVID-19 pandemic under control.
403 However frequent emergence of SARS-CoV-2 variants requires adjunct approaches to
404 deal with infections. Micronutrient supplementation could be an effective and safe
405 strategy. Ferric ammonium citrate (FAC) was shown to inhibit a number of RNA viruses
406 including Influenza A virus, Zika virus and Hepatitis C virus in both cell culture and
407 animal models and it was shown that treatment with FAC perturbed endosomal release
408 of the internalized virus in the case of Influenza A virus([55](#)). SARS-CoV-2 nsp12 has
409 been shown to bind Fe and Iron-Sulfur cluster binding was required for optimal activity
410 of the RdRp([56](#)). However, there have been no direct demonstration of the effect of Fe
411 salts on either the RdRp activity in vitro on in lung epithelial cells. We show here that
412 FeSO_4 inhibited both RdRp activity and infection in Calu-3 cells. The inhibitory
413 concentration in cell culture was much below the *in vitro* IC_{50} concentrations. Contrary to

414 our findings, iron overload is considered as a risk factor for severe COVID-19 disease
415 and iron chelation has been proposed as a treatment option(57) (58). Therefore, the
416 exact mechanism of action behind inhibition of SARS-CoV-2 infection by FeSO₄
417 warrants further investigation. Interestingly, CuCl₂ which inhibited RdRp activity at 1 mM
418 also inhibited virus infection in Calu-3 cells at 20 times below this concentration
419 indicating that both Fe and Cu ions may act on SARS-CoV-2 both directly and via host
420 pathways. Previous reports have shown that copper-coated surfaces can inactivate
421 SARS-CoV-2(59) and other enveloped and non-enveloped viruses are susceptible to
422 copper ions either due to direct effect of copper ions on viral particles or viral genome or
423 due to induction of reactive oxygen species. Therefore, copper supplementation during
424 viremic phase may further augment antiviral strategies for COVID-19(60-62). Zinc
425 acetate, in combination with zinc ionophore pyrithione, was shown to inhibit SARS-CoV-
426 1 infection in Vero E6 cells and zinc ions was shown to directly inhibit RdRp activity of
427 SARS-CoV-1(42). SARS-CoV-2 proteome encodes for a number of metalloproteins
428 including zinc-binding proteins such as nsp2, nsp9, nsp10/16 complex, nsp12 and
429 proofreading exoribonuclease nsp14 (Please see Uniprot ID: P0DTD1 · R1AB_SARS2).
430 Some of the critical aspects of viral replication such as RdRp activity, 2'-O methylation,
431 capping depends on intracellular zinc(63, 64). Zinc ejection from some of these enzymes
432 has been proposed as an attractive antiviral target(65). However, despite ZnSO₄
433 inhibiting the activity of SARS-CoV-2 RdRp *in vitro*, we saw no effect on SARS-CoV-2
434 Delta and Omicron variants at 50 μM concentration. Whether higher concentrations of
435 zinc salts are required to achieve significant inhibition of these variants in cell culture
436 needs further investigation.

437

438 **ONLINE METHODS**

439 **Human Ethics**

440 The study was approved by the Institutional Ethics Committee for human research at
441 ESIC Hospital and Medical College (No.134/R/10/IEC/22/2021/02) and THSTI (THS
442 1.8.1/ (93)). Informed consent was obtained from all the participants.

443

444 **Human Samples**

445 ChAdOx1 nCoV-19 cohort: Subjects (age 25-46) visiting ESIC Medical College &
446 Hospital, Faridabad for vaccination were enrolled in the study after obtaining written
447 informed consent. About 4 ml of whole blood was collected for serum preparation four
448 weeks after the first and second dose of vaccination and a follow-up sample was
449 collected after six months. Nasopharyngeal/Oropharyngeal (NP/OP) swabs were
450 collected from patients with symptoms of COVID-19 infection. Total RNA was isolated to
451 detect SARS-CoV-2 using COVIDsure multiplex real-time RT-PCR kit (Triviron
452 Healthcare) either at Employees State Insurance Corporation (ESIC) Medical College &
453 Hospital or at the bioassay laboratory Translational Health Science and Technology
454 Institute, Faridabad. Clinical presentations were mild to moderate fever, dry cough, and
455 loss of sense of smell and taste. All COVID-19 positive patients were self-isolated and
456 recovered without any need for clinical intervention or hospitalization. A follow-up blood
457 sample was collected after 3-4 weeks post-recovery in both second (May 2021) and
458 third wave (Feb 2022).

459

460 **Cells and Viruses**

461 Calu-3 cells and Vero E6 cells were procured from American Type Culture Collection
462 (ATCC) and European Collection of Authenticated Cell Cultures (ECACC) respectively.
463 Both cell lines were maintained in Dulbecco's Modified Eagle Medium (DMEM)
464 (HiMedia) supplemented with 10% fetal bovine serum (FBS), 100 units/ml of Penicillin-
465 Streptomycin-Glutamine (PSG), and 1X non-essential amino acid (NEAA). In addition to
466 this, 25 mM HEPES was added to the Vero E6 culture medium. Different variants of
467 SARS-CoV-2 i.e., ancestral (B.6, Genbank: MW422884.1), kappa (B.1.617.1, Genbank:
468 MZ356902.1), delta (B.1.617.2, Genbank: MZ356566.1), and omicron (B.1.529; BA.1
469 GISAID: EPI_ISL_6716902 and BA.2 GISAID ID: EPI_ISL_87638432 sub-lineages)
470 were propagated in Calu-3 cells and passaging was limited to five passages.

471

472 **Growth curve experiment**

473 All experiments with infectious SARS-CoV-2 virus were performed at the infectious
474 disease research facility, which is a biosafety level-3 laboratory. Calu-3 cells were
475 seeded in 48-well or 24-well plates and infected with indicated SARS-CoV-2 virus
476 isolates two days post-seeding. Infected culture supernatants were collected at
477 indicated time points to estimate viral titers by plaque assay on Vero E6 cells. Total
478 RNA was extracted from cells collected at respective time points and viral copy
479 numbers (N gene) were estimated by quantitative RT-PCR using RNase P gene for
480 normalization as described previously([66](#)).

481

482 **Plaque assay Method**

483 Vero E6 cells were used for virus titration by plaque assay method. The supernatants
484 were collected from infected cells at indicated time points. The supernatants were ten-
485 fold diluted using growth medium with 2% FBS. After 1h of viral adsorption, virus
486 inoculum was removed. Overlay medium with 0.5% carboxymethylcellulose (CMC) was
487 added to the cells. The plates were incubated at 37° C for 48 h for all SARS-CoV-2
488 variants except omicron where the incubation period was 72 h. After the incubation
489 period, cells were fixed with 3.7% formaldehyde solution followed by incubation for 10
490 min at room temperature (RT). Cells were stained with crystal violet solution and
491 plaques were observed.

492

493 **Trans-epithelial electrical resistance (TEER) and confocal microscopy**

494 Calu-3 cells were seeded at 30,000 on 3 µm pore size transwell inserts (Corning - 3415)
495 and grown for 21 days. TEER was monitored on alternate days using a chopstick
496 electrode (Millipore) and the medium was changed on the same day. On day 22 post-
497 seeding, cells were infected with indicated variants of SARS-CoV-2 at 0.3 MOI. After 1 h
498 of viral adsorption, virus inoculum was removed and cells were washed twice with 1X
499 PBS. Growth medium with 10% FBS was added to the cells. TEER was monitored at
500 indicated time points. At 48 h pi, culture inserts were washed with cold 1X PBS and
501 incubated with cold methanol at -20°C for 20 minutes. Cells were further incubated with
502 IMF buffer (20 mM HEPES, pH 7.5, 0.1% Triton X-100, 150 mM sodium chloride, 5 mM
503 EDTA and 0.02% sodium azide as a preservative) for 5 min at room temperature (RT)
504 and all further washes were performed with IMF buffer. Non-specific antibody binding
505 sites were blocked by incubating cells with IMF buffer containing 2% normal goat serum

506 for 10 min at RT. Membranes were cut out using a scalpel blade and transferred to a
507 48-well plate. Cells were washed three times followed by incubation with antibodies
508 against SARS-CoV-2 nucleocapsid, occludin, and β -catenin in IMF buffer for 1 h at RT.
509 Cells were washed followed by incubation with secondary antibodies tagged with Alexa
510 Fluor 488/568/633 (Molecular probes) for 30 min at RT by avoiding exposure to light.
511 Cells were washed with IMF buffer three times and stained with DAPI at 1:10,000
512 dilution for 10 min. Cells were washed with PBS, mounted on glass slide using antifade
513 solution (Molecular probes), and images were captured at 100X magnification using
514 FV3000 confocal microscope (Olympus). Acquired images were processed using
515 CellSens software (Olympus) and projections of Z-stack (maximum intensity) are shown
516 in figures.

517

518 **Focus-forming units (FFU) assay**

519 The supernatants were collected from infected cells at indicated time points. The
520 supernatants were ten-fold diluted using growth medium with 2% FBS. After 1h of viral
521 adsorption, virus inoculum was removed. Overlay medium with 1.5%
522 carboxymethylcellulose (CMC) for all SARS-CoV-2 variants except for Omicron where
523 1% CMC was used. The plates were incubated at 37° C for 28 h for omicron and 24 h
524 for all other SARS-CoV-2 variants. After incubation time, cells were fixed with
525 formaldehyde solution followed by permeabilization with IMF buffer for 20 min
526 incubation. Further, cells were stained with anti-spike RBD rabbit polyclonal antibody
527 dilution at a dilution of 1:2000 for 1 h, followed by incubation with secondary antibody
528 i.e., Alexa flour 488-conjugated anti-rabbit antibody at 1:500 dilution for 1 h. For omicron

529 isolate, anti-nucleocapsid primary antibody was used at a dilution of 1:2000. This was
530 followed by incubation with secondary antibody i.e., Alexa flour 488-conjugated goat
531 anti-mouse IgG secondary antibody at 1:500 dilution. Fluorescent foci indicating
532 infected cells were observed and counted using AIDiSpot reader using FITC channel.

533

534 **Western blot**

535 At indicated time points, cells were washed twice with cold PBS on ice and were
536 collected in 200 μ l of 1X laemmli buffer with protease inhibitor mix and 1 mM PMSF.
537 Lysates were incubated on ice for 10 min and sonicated (amplitude: 30%, time: 5 sec
538 ON/10 sec OFF, total cycles: 10) on ice. Cell lysates were centrifuged at 13,000 x g for
539 15 min at 4 °C. 5 μ l of each sample was resolved on 12% SDS-PAGE. Gels were
540 transferred onto PVDF membrane for 2 h and the SARS-CoV-2 infection was analyzed
541 by probing the blot with the SARS-CoV-2 nucleocapsid antibody. GAPDH antibody was
542 used as a loading control. Primary antibody incubation was followed by HRP-conjugated
543 secondary antibodies. Luminol-based chemiluminescent substrate was added to the
544 blots and signals were detected using a gel documentation system (Azure biosystems
545 C400).

546

547 **Virus entry experiment**

548 Calu-3 cells were infected with the above-indicated variants of SARS-CoV-2 at 5 MOI.
549 After 1 h of viral adsorption, the virus inoculum was removed and cells were washed
550 with 1X PBS. Cells were trypsinized and collected in complete growth medium and
551 centrifuged at 200 x g for 5 min. The supernatants were discarded and the cell pellets

552 were washed twice with 1X PBS followed by centrifugation. In the final step, the cell
553 pellets were collected in 350 μ l lysis buffer. Viral copy numbers were estimated as
554 described in the above section.

555

556 **Quantitative RT-PCR Assay**

557 Calu-3 cells were infected with ancestral, delta, and omicron variants of SARS-CoV-2 at
558 a MOI of 0.3. At indicated time points, the supernatant was collected for estimating viral
559 titres by plaque assay, and cells were collected in lysis buffer provided in the RNA
560 isolation kit as described in the above section. For interferon pathway, 500 ng RNA was
561 used to erase genomic DNA and reverse transcribed using PrimeScript RT reagent kit
562 with gDNA eraser kit. The indicated genes were quantitated by SYBR green chemistry
563 and GAPDH was used as housekeeping control gene for normalization. The list of
564 primers used is provided in the key resources table. Data were analyzed using the
565 $\Delta\Delta C_T$ method, where C_T is cycle threshold.

566

567 **TEER in air-liquid interface condition and confocal microscopy**

568 Calu-3 cells were seeded at a density of 30,000 cells in 3 μ m pore size polycarbonate
569 membranes in 24 well-plate with corresponding 200 μ l culture medium on the apical
570 side and 800 μ l culture medium was added into the basolateral chamber. Cells were left
571 to grow submerged for 8 days. The culture medium was changed on alternate days and
572 TEER values were monitored. On day 9, the medium was removed from the apical
573 chamber to obtain air-liquid interface (ALI) conditions. Cells were cultured in ALI
574 conditions for 20 days. After obtaining stable TEER values, on day 21, cells were

575 washed with 1X Hanks' balanced salt solution (HBSS). Cells were infected with either
576 the Delta or the Omicron variants of SARS-CoV2 at 0.3 MOI. After 1 h of viral
577 adsorption, cells were washed twice with HBSS, and culture medium was added to the
578 basolateral side. To assess the effect of SARS-CoV-2 on epithelial cells barrier, TEER
579 was monitored at indicated time points. Supernatants were collected from basolateral
580 surface for measuring viral titres. At 36 h pi, cells were washed with cold PBS and fixed
581 in ice-cold methanol for 20 min at -20°C . The cells were stained against junction
582 proteins along with nucleocapsid antibodies as described above in the confocal
583 microscopy section.

584

585 **Quantitative Nucleoprotein (N) and RBD ELISA**

586 ELISA for nucleocapsid (N) and recombinant spike protein receptor-binding domain
587 (RBD) was performed as described earlier. Detailed method description is provided in
588 previous reports([13](#), [67](#)).

589

590 **Virus microneutralization assay**

591 Virus microneutralization assay by focus reduction neutralization titer (FRNT) assay
592 using indicating virus isolates was performed as described earlier([13](#), [67](#)).

593

594 **RNA-dependent RNA polymerase (RdRp) activity assay**

595 The Quant-iT™ PicoGreen® dsDNA reagent was used to establish a fluorophore-based
596 RdRp activity system. Adenosine 5'-triphosphate (ATP) was purchased from Sigma–
597 Aldrich. RdRp RNA template with self-hairpin primer used for RdRp assays in this study

621 Data were analysed and charts were prepared using GraphPad Prism software. All
622 experiments were performed with two or more replicates and graphs have been
623 prepared representing data from at least two independent experiments. Figure legends
624 indicate error bars and statistical tests conducted for estimating P values.

625

626 **Data availability**

627 All the data are presented in this manuscript. Source data will be made available upon
628 request.

629

630 **ACKNOWLEDGEMENTS**

631 We thank all the members of bioassay lab, COVID-19 testing team, Amresh Kumar
632 Singh Maniram and other members of the Clinical and Cellular Virology lab for technical
633 support. We thank Neha Garg and Shamsheer Singh for data management. We thank all
634 the patients who consented to participate in the study.

635

636 **AUTHOR CONTRIBUTIONS**

637 JS, AP, AA, MB, PK and KP performed all cell culture and infection experiments. CR
638 purified recombinant proteins and performed the *in vitro* RdRp assays. PC, PD, RM, PM
639 performed SARS-CoV-2 genome sequencing and analysis. AKP supervised and
640 coordinated the study at the clinical site and contributed reagents. RP designed the
641 sequencing experiments, supervised the team and analyzed the data. GRM conceived
642 the study, designed the experiments, and analyzed the data. JS, AP, AA and GRM

643 wrote the manuscript. All authors have reviewed and approved the final version of the
644 manuscript.

645

646 **FUNDING INFORMATION**

647 This work was supported by the Department of Biotechnology (DBT) grants through
648 IndCEPI Mission (BT/MB/CEPI/2016), Translational Research Program
649 (BT/PR30159/MED/15/188/2018) and BT/PR40384/COT/142/5/2020. Funding support
650 was also obtained from Global Immunology and Immune Sequencing for Epidemic
651 Response (INV-030592). RP acknowledges funding support from IUSSTF (CLP-0033)
652 and BMGF (CLP-0036). The funders had no role in study design, data collection and
653 interpretation or the decision to submit the work for publication.

654

655 **CONFLICT OF INTEREST STATEMENT**

656 The authors have declared that no conflict of interest exists.

657

658 **REFERENCES**

- 659 1. Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al.
660 Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at
661 June 2021. *Euro Surveill.* 2021 Jun;26(24). PubMed PMID: 34142653. Pubmed Central
662 PMCID: PMC8212592. Epub 2021/06/19.
- 663 2. Fisman DN, Tuite AR. Progressive Increase in Virulence of Novel SARS-CoV-2
664 Variants in Ontario, Canada. *medRxiv.* 2021:2021.07.05.21260050.
- 665 3. Li B, Deng A, Li K, Hu Y, Li Z, Xiong Q, et al. Viral infection and transmission in a
666 large well-traced outbreak caused by the Delta SARS-CoV-2 variant. *medRxiv.*
667 2021:2021.07.07.21260122.
- 668 4. Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, Mishra S, et al. SARS-CoV-2
669 B.1.617.2 Delta variant emergence, replication and sensitivity to neutralising antibodies.
670 *bioRxiv.* 2021:2021.05.08.443253.

- 671 5. Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al.
672 Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv.
673 2021:2021.05.22.21257658.
- 674 6. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et
675 al. Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal
676 antibodies and sera from convalescent and vaccinated individuals. bioRxiv.
677 2021:2021.05.26.445838.
- 678 7. Supasa P, Zhou D, Dejnirattisai W, Liu C, Mentzer AJ, Ginn HM, et al. Reduced
679 neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell.
680 2021 Apr 15;184(8):2201-11 e7. PubMed PMID: 33743891. Pubmed Central PMCID:
681 PMC7891044. Epub 2021/03/22.
- 682 8. Mahase E. Covid-19: What do we know about omicron sublineages? BMJ. 2022
683 Feb 11;376:o358. PubMed PMID: 35149516. Epub 20220211.
- 684 9. Cele S, Jackson L, Khan K, Khoury DS, Moyo-Gwete T, Tegally H, et al. SARS-
685 CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited
686 neutralization and requires ACE2 for infection. medRxiv. 2021 Dec 11. PubMed PMID:
687 34909788. Pubmed Central PMCID: PMC8669855. Epub 20211211.
- 688 10. Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, et al. Reduced
689 neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.
690 Lancet. 2021 Dec 20. PubMed PMID: 34942101. Pubmed Central PMCID:
691 PMC8687667. Epub 20211220.
- 692 11. Iketani S, Liu L, Guo Y, Liu L, Huang Y, Wang M, et al. Antibody Evasion
693 Properties of SARS-CoV-2 Omicron Sublineages. bioRxiv. 2022:2022.02.07.479306.
- 694 12. Medigeshi GR, Batra G, Murugesan DR, Thiruvengadam R, Chattopadhyay S,
695 Das B, et al. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies
696 induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post
697 6-months. eBioMedicine. 2022;78.
- 698 13. Singh J, Shaman H, Anantharaj A, Singh B, Pargai K, Kumar P, et al. Infection
699 with Omicron variant generates neutralizing antibodies to BA.1 and BA.2 sub-lineages
700 and induces higher levels of cross-neutralizing antibodies to Delta variant. medRxiv.
701 2022:2022.01.28.22269990.
- 702 14. Yu J, Collier AY, Rowe M, Mardas F, Ventura JD, Wan H, et al. Neutralization of
703 the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. N Engl J Med. 2022 Mar 16.
704 PubMed PMID: 35294809. Epub 20220316.
- 705 15. Carroll T, Fox D, van Doremalen N, Ball E, Morris MK, Sotomayor-Gonzalez A, et
706 al. The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral
707 B.1 (614G) in Syrian hamsters. PLoS Pathog. 2022 Feb;18(2):e1009914. PubMed
708 PMID: 35143587. Pubmed Central PMCID: PMC8865701. Epub 20220210.
- 709 16. Escalera A, Gonzalez-Reiche AS, Aslam S, Mena I, Laporte M, Pearl RL, et al.
710 Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and
711 virus transmission. Cell Host Microbe. 2022 Mar 9;30(3):373-87 e7. PubMed PMID:
712 35150638. Pubmed Central PMCID: PMC8776496. Epub 20220121.
- 713 17. Halfmann PJ, Iida S, Iwatsuki-Horimoto K, Maemura T, Kiso M, Scheaffer SM, et
714 al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters.
715 Nature. 2022 Mar;603(7902):687-92. PubMed PMID: 35062015. Epub 20220121.

- 716 18. Port JR, Yinda CK, Avanzato VA, Schulz JE, Holbrook MG, van Doremalen N, et
717 al. Increased small particle aerosol transmission of B.1.1.7 compared with SARS-CoV-2
718 lineage A in vivo. *Nat Microbiol.* 2022 Feb;7(2):213-23. PubMed PMID: 35017676. Epub
719 20220111.
- 720 19. Saito A, Irie T, Suzuki R, Maemura T, Nasser H, Uriu K, et al. Enhanced
721 fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. *Nature.* 2022
722 Feb;602(7896):300-6. PubMed PMID: 34823256. Pubmed Central PMCID:
723 PMC8828475. Epub 20211125.
- 724 20. Ulrich L, Halwe NJ, Taddeo A, Ebert N, Schon J, Devisme C, et al. Enhanced
725 fitness of SARS-CoV-2 variant of concern Alpha but not Beta. *Nature.* 2022
726 Feb;602(7896):307-13. PubMed PMID: 34937050. Pubmed Central PMCID:
727 PMC8828469. Epub 20211222.
- 728 21. Laskar R, Ali S. Phylo-geo-network and haplogroup analysis of 611 novel
729 coronavirus (SARS-CoV-2) genomes from India. *Life Sci Alliance.* 2021 May;4(5).
730 PubMed PMID: 33727249. Pubmed Central PMCID: PMC7994317. Epub 2021/03/18.
- 731 22. Pattabiraman C, Habib F, P KH, Rasheed R, Prasad P, Reddy V, et al. Genomic
732 epidemiology reveals multiple introductions and spread of SARS-CoV-2 in the Indian
733 state of Karnataka. *PLoS One.* 2020;15(12):e0243412. PubMed PMID: 33332472.
734 Pubmed Central PMCID: PMC7746284 participate as a volunteer in this study and his
735 employer neither had access to data, nor any say in the design of the study or the
736 decision to publish. This does not alter our adherence to PLOS ONE policies on sharing
737 data and materials. All other authors are employees of state (PD, PK) or central
738 government. The employers had no role in the design of the study or the decision to
739 publish. The authors declare that they do not have any other financial or non-financial
740 relationships that could present a conflict of interest. Epub 2020/12/18.
- 741 23. Anantharaj A, Gujjar S, Kumar S, Verma N, Wangchuk J, Khan NA, et al.
742 Kinetics of viral load, immunological mediators and characterization of a SARS-CoV-2
743 isolate in mild COVID-19 patients during acute phase of infection. *medRxiv.*
744 2020:2020.11.05.20226621.
- 745 24. Dhar MS, Marwal R, Radhakrishnan V, Ponnusamy K, Jolly B, Bhoyar RC, et al.
746 Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in
747 Delhi, India. *medRxiv.* 2021:2021.06.02.21258076.
- 748 25. Zhu N, Wang W, Liu Z, Liang C, Wang W, Ye F, et al. Morphogenesis and
749 cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells. *Nat*
750 *Commun.* 2020 Aug 6;11(1):3910. PubMed PMID: 32764693. Pubmed Central PMCID:
751 PMC7413383. Epub 2020/08/09.
- 752 26. Liu Y, Liu J, Johnson BA, Xia H, Ku Z, Schindewolf C, et al. Delta spike P681R
753 mutation enhances SARS-CoV-2 fitness over Alpha variant. *bioRxiv.* 2021 Sep 5.
754 PubMed PMID: 34462752. Pubmed Central PMCID: PMC8404900. Epub 20210905.
- 755 27. Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, Ferreira I, et al. SARS-CoV-2
756 B.1.617.2 Delta variant replication and immune evasion. *Nature.* 2021 Sep 6. PubMed
757 PMID: 34488225. Epub 2021/09/07.
- 758 28. Li B, Deng A, Li K, Hu Y, Li Z, Xiong Q, et al. Viral infection and transmission in a
759 large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. *medRxiv.*
760 2021:2021.07.07.21260122.

- 761 29. Suzuki R, Yamasoba D, Kimura I, Wang L, Kishimoto M, Ito J, et al. Attenuated
762 fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. *Nature*. 2022
763 Mar;603(7902):700-5. PubMed PMID: 35104835. Epub 20220201.
- 764 30. Bojkova D, Widera M, Ciesek S, Wass MN, Michaelis M, Cinatl J, Jr. Reduced
765 interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta
766 variant of SARS-CoV-2 isolates. *Cell Res*. 2022 Mar;32(3):319-21. PubMed PMID:
767 35064226. Pubmed Central PMCID: PMC8781709. Epub 20220121.
- 768 31. Zhao H, Lu L, Peng Z, Chen LL, Meng X, Zhang C, et al. SARS-CoV-2 Omicron
769 variant shows less efficient replication and fusion activity when compared with Delta
770 variant in TMPRSS2-expressed cells. *Emerg Microbes Infect*. 2022 Dec;11(1):277-83.
771 PubMed PMID: 34951565. Pubmed Central PMCID: PMC8774049.
- 772 32. Vanderheiden A, Ralfs P, Chirkova T, Upadhyay AA, Zimmerman MG, Bedoya S,
773 et al. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway
774 Epithelial Cultures. *J Virol*. 2020 Sep 15;94(19). PubMed PMID: 32699094. Pubmed
775 Central PMCID: PMC7495371. Epub 2020/07/24.
- 776 33. Schroeder S, Pott F, Niemeyer D, Veith T, Richter A, Muth D, et al. Interferon
777 antagonism by SARS-CoV-2: a functional study using reverse genetics. *Lancet Microbe*.
778 2021 May;2(5):e210-e8. PubMed PMID: 33969329. Pubmed Central PMCID:
779 PMC8096348. Epub 20210304.
- 780 34. Anantharaj A, Gujjar S, Verma N, Khan NA, Shaman H, Sharanabasava P, et al.
781 Resolution of viral load in mild COVID-19 patients is associated with both innate and
782 adaptive immune responses. *Journal of Clinical Virology*. 2022
783 2022/01/01/;146:105060.
- 784 35. Bojkova D, Rothenburger T, Ciesek S, Wass MN, Michaelis M, Cinatl J. SARS-
785 CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment.
786 *bioRxiv*. 2022:2022.01.20.477067.
- 787 36. Desingu PA, Nagarajan K, Dhama K. Emergence of Omicron third lineage BA.3
788 and its importance. *Journal of Medical Virology*. 2022;94(5):1808-10.
- 789 37. Medigeshi G, Batra G, Murugesan DR, Thiruvengadam R, Chattopadhyay S, Das
790 B, et al. Sub-optimal Neutralisation of Omicron (B.1.1.529) Variant by Antibodies
791 induced by Vaccine alone or SARS-CoV-2 Infection plus Vaccine (Hybrid Immunity)
792 post 6-months. *medRxiv*. 2022:2022.01.04.22268747.
- 793 38. Lyngse FP, Kirkeby CT, Denwood M, Christiansen LE, Mølbak K, Møller CH, et
794 al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence
795 from Danish Households. *medRxiv*. 2022:2022.01.28.22270044.
- 796 39. Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, et al. Virological
797 characteristics of SARS-CoV-2 BA.2 variant. *bioRxiv*. 2022:2022.02.14.480335.
- 798 40. Arora P, Zhang L, Rocha C, Sidarovich A, Kempf A, Schulz S, et al. Comparable
799 neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3. *The*
800 *Lancet Infectious Diseases*.
- 801 41. Chaturvedi UC, Shrivastava R. Interaction of viral proteins with metal ions: role in
802 maintaining the structure and functions of viruses. *FEMS Immunol Med Microbiol*. 2005
803 Feb 1;43(2):105-14. PubMed PMID: 15681139. Pubmed Central PMCID: PMC7110337.
- 804 42. te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert
805 MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc
806 ionophores block the replication of these viruses in cell culture. *PLoS Pathog*. 2010 Nov

- 807 4;6(11):e1001176. PubMed PMID: 21079686. Pubmed Central PMCID: PMC2973827.
808 Epub 2010/11/17.
- 809 43. Hillen HS, Kokic G, Farnung L, Dienemann C, Tegunov D, Cramer P. Structure
810 of replicating SARS-CoV-2 polymerase. *Nature*. 2020 Aug;584(7819):154-6. PubMed
811 PMID: 32438371. Epub 20200521.
- 812 44. Shimizu H, Saito A, Mikuni J, Nakayama EE, Koyama H, Honma T, et al.
813 Discovery of a small molecule inhibitor targeting dengue virus NS5 RNA-dependent
814 RNA polymerase. *PLOS Neglected Tropical Diseases*. 2019;13(11):e0007894.
- 815 45. Eydoux C, Fattorini V, Shannon A, Le TT, Didier B, Canard B, et al. A
816 fluorescence-based high throughput-screening assay for the SARS-CoV RNA synthesis
817 complex. *J Virol Methods*. 2021 Feb;288:114013. PubMed PMID: 33166547. Pubmed
818 Central PMCID: PMC7833800. Epub 20201106.
- 819 46. Nealon J, Cowling BJ. Omicron severity: milder but not mild. *The Lancet*.
820 2022;399(10323):412-3.
- 821 47. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological
822 memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science*. 2021 Feb
823 5;371(6529). PubMed PMID: 33408181. Pubmed Central PMCID: PMC7919858. Epub
824 20210106.
- 825 48. Chen J, Wei GW. Omicron BA.2 (B.1.1.529.2): high potential to becoming the
826 next dominating variant. *ArXiv*. 2022 Feb 10. PubMed PMID: 35169598. Pubmed
827 Central PMCID: PMC8845508. Epub 20220210.
- 828 49. Gao Y, Cai C, Grifoni A, Muller TR, Niessl J, Olofsson A, et al. Ancestral SARS-
829 CoV-2-specific T cells cross-recognize the Omicron variant. *Nat Med*. 2022 Jan 14.
830 PubMed PMID: 35042228. Epub 20220114.
- 831 50. GeurtsvanKessel CH, Geers D, Schmitz KS, Mykytyn AZ, Lamers MM, Bogers S,
832 et al. Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19
833 vaccine recipients. *Sci Immunol*. 2022 Feb 3:eabo2202. PubMed PMID: 35113647.
834 Epub 20220203.
- 835 51. Broggi A, Ghosh S, Sposito B, Spreafico R, Balzarini F, Lo Cascio A, et al. Type
836 III interferons disrupt the lung epithelial barrier upon viral recognition. *Science*. 2020
837 Aug 7;369(6504):706-12. PubMed PMID: 32527925. Pubmed Central PMCID:
838 PMC7292499. Epub 2020/06/13.
- 839 52. Major J, Crotta S, Llorian M, McCabe TM, Gad HH, Priestnall SL, et al. Type I
840 and III interferons disrupt lung epithelial repair during recovery from viral infection.
841 *Science*. 2020 Aug 7;369(6504):712-7. PubMed PMID: 32527928. Pubmed Central
842 PMCID: PMC7292500. Epub 2020/06/13.
- 843 53. Hui KPY, Ho JCW, Cheung MC, Ng KC, Ching RHH, Lai KL, et al. SARS-CoV-2
844 Omicron variant replication in human bronchus and lung ex vivo. *Nature*. 2022
845 Mar;603(7902):715-20. PubMed PMID: 35104836. Epub 20220201.
- 846 54. McMahan K, Giffin V, Tostanoski LH, Chung B, Siamatu M, Suthar MS, et al.
847 Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters. *Med*. 2022
848 2022/04/08;3(4):262-8.e4.
- 849 55. Wang H, Li Z, Niu J, Xu Y, Ma L, Lu A, et al. Antiviral effects of ferric ammonium
850 citrate. *Cell Discov*. 2018;4:14. PubMed PMID: 29619244. Pubmed Central PMCID:
851 PMC5871618. Epub 20180327.

- 852 56. Maio N, Lafont BAP, Sil D, Li Y, Bollinger JM, Jr., Krebs C, et al. Fe-S cofactors
853 in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets.
854 Science. 2021 Jul 9;373(6551):236-41. PubMed PMID: 34083449. Pubmed Central
855 PMCID: PMC8892629. Epub 20210603.
- 856 57. Bastin A, Shiri H, Zanganeh S, Fooladi S, Momeni Moghaddam MA, Mehrabani
857 M, et al. Iron Chelator or Iron Supplement Consumption in COVID-19? The Role of Iron
858 with Severity Infection. Biol Trace Elem Res. 2021 Nov 25. PubMed PMID: 34825316.
859 Pubmed Central PMCID: PMC8614629. Epub 20211125.
- 860 58. Habib HM, Ibrahim S, Zaim A, Ibrahim WH. The role of iron in the pathogenesis
861 of COVID-19 and possible treatment with lactoferrin and other iron chelators. Biomed
862 Pharmacother. 2021 Apr;136:111228. PubMed PMID: 33454595. Pubmed Central
863 PMCID: PMC7836924. Epub 20210113.
- 864 59. Bryant C, Wilks SA, Keevil CW. Rapid inactivation of SARS-CoV-2 on copper
865 touch surfaces determined using a cell culture infectivity assay. bioRxiv.
866 2021:2021.01.02.424974.
- 867 60. Govind V, Bharadwaj S, Sai Ganesh MR, Vishnu J, Shankar KV, Shankar B, et
868 al. Antiviral properties of copper and its alloys to inactivate covid-19 virus: a review.
869 BioMetals. 2021 2021/12/01;34(6):1217-35.
- 870 61. Raha S, Mallick R, Basak S, Duttaroy AK. Is copper beneficial for COVID-19
871 patients? Medical Hypotheses. 2020 2020/09/01/;142:109814.
- 872 62. Sagripanti JL, Routson LB, Lytle CD. Virus inactivation by copper or iron ions
873 alone and in the presence of peroxide. Appl Environ Microbiol. 1993 Dec;59(12):4374-6.
874 PubMed PMID: 8285724. Pubmed Central PMCID: PMC195916.
- 875 63. Viswanathan T, Misra A, Chan SH, Qi S, Dai N, Arya S, et al. A metal ion orients
876 SARS-CoV-2 mRNA to ensure accurate 2'-O methylation of its first nucleotide. Nat
877 Commun. 2021 Jun 2;12(1):3287. PubMed PMID: 34078893. Pubmed Central PMCID:
878 PMC8172916. Epub 20210602.
- 879 64. Bouvet M, Lugari A, Posthuma CC, Zevenhoven JC, Bernard S, Betzi S, et al.
880 Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes. J
881 Biol Chem. 2014 Sep 12;289(37):25783-96. PubMed PMID: 25074927. Pubmed Central
882 PMCID: PMC4162180. Epub 20140729.
- 883 65. Chen T, Fei CY, Chen YP, Sargsyan K, Chang CP, Yuan HS, et al. Synergistic
884 Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir. ACS
885 Pharmacol Transl Sci. 2021 Apr 9;4(2):898-907. PubMed PMID: 33855277. Pubmed
886 Central PMCID: PMC8009100. Epub 20210326.
- 887 66. Anantharaj A, Das SJ, Sharanabasava P, Lodha R, Kabra SK, Sharma TK, et al.
888 Visual Detection of SARS-CoV-2 RNA by Conventional PCR-Induced Generation of
889 DNAzyme Sensor. Front Mol Biosci. 2020 2020-December-23;7(444):586254. PubMed
890 PMID: 33425988. Pubmed Central PMCID: PMC7793695. Epub 2021/01/12. English.
- 891 67. Das S, Singh J, Shaman H, Singh B, Anantharaj A, Sharanabasava P, et al.
892 Antibody response after a single dose of BBV152 vaccine negatively correlates with
893 pre-existing antibodies and induces a significant but low levels of neutralizing antibodies
894 to Omicron variant. medRxiv. 2022:2022.02.07.22270612.

895

896 SUPPLEMENTARY INFORMATION

897 Supplementary methods and Supplementary figure legends have been provided as a
898 separate file.

899

900 **FIGURE LEGENDS**

901 **Figure 1: Growth curve analysis of B.6, B.1.617.1, and B.1.617.2 variants in Calu-3**
902 **cells.** Calu-3 cells were infected with 0.01 MOI of SARS-CoV-2 virus B.6, B.1.617.1
903 (Kappa), and B.1.617.2 (Delta) variants. (A) Virus titer in the culture supernatant
904 collected at indicated time-points were estimated by plaque assay. Error bars represent
905 geometric mean with 95% CI. (B) Sub-genomic RNA of N gene was estimated by qRT-
906 PCR. *RNAse P* was used as internal control for normalization. Error bars represent
907 geometric mean with 95% CI. (C) Calu-3 cells grown on transwell inserts were infected
908 with above variants at 0.3 MOI and TEER was monitored at indicated time points.
909 Values (Mean \pm SD) are represented as relative to time zero before infection and
910 statistical significance was determined by comparing the zero hour and 48 h readings
911 by two-way ANOVA with Dunnett's multiple comparisons test. (D) Viral titers were
912 measured in supernatants at 48 h pi by focus-forming units. Data are from two or three
913 independent experiments (Mean \pm SD). ns: non-significant; ** $P < 0.01$; **** $P < 0.0001$.

914

915 **Figure 2: Kappa and Delta variants of SARS-CoV-2 disrupt epithelial junctions.**

916 Calu-3 cells were grown on transwell inserts and infected with indicated variants of
917 SARS-CoV-2 at 0.3 MOI. At 48 h pi, cells were fixed and stained with occludin and β -
918 catenin antibodies. Nucleocapsid antibody was used to visualize the SARS-CoV-2
919 infection. Appropriate Alexa Fluor dye-conjugated secondary antibodies were used for

920 visualization. Nuclei were stained with DAPI. Images were captured at 100X
921 magnification. Images were analyzed using cellSens software and Z-projection at
922 maximum intensity images are shown in the figure. Scale bar is 10 μ M.

923

924 **Figure 3: Growth kinetics of B.6, B.1.617.2, and B.1.1.529 variants in Calu-3 cells.**

925 (A) Calu-3 cells were infected with above variants of SARS-CoV-2 at 0.3 MOI. Cells
926 were collected at indicated time points and total RNA was isolated to estimate *N* gene
927 copy numbers by RT-qPCR. *RNase P* was used as a housekeeping control for
928 normalization. Error bars represent geometric mean with 95% CI. (B) Viral titers were
929 measured in supernatants by plaque assay. Error bars represent geometric mean with
930 95% CI. Statistical significance was estimated by two-way ANOVA with Dunnett's
931 multiple comparisons test. (C) Western blot analysis of cell lysates prepared from
932 infected cells at indicated time points to detect the expression of SARS-CoV-2
933 nucleocapsid. GAPDH was used as a loading control. Numbers on the left indicate the
934 size of the bands in molecular weight marker. (D) Calu-3 cells were infected at 5 MOI
935 and the amount of internalized RNA was estimated by RT-qPCR as described above.
936 Data are from two independent experiments. Error bars represent geometric mean with
937 95% CI. Statistical significance was estimated by Kruskal-Wallis test with Dunn's
938 multiple comparison test. ns: non-significant, * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, ****
939 $P < 0.0001$.

940

941 **Figure 4: Antiviral response with B.6, B.1.617.2, and B.1.1.529 variants.** Calu-3

942 cells were infected with indicated variants of SARS-CoV-2 at 0.3 MOI. Cells were

943 collected at indicated time-points and total RNA was isolated. RT-qPCR was set up to
944 determine the expression of (A) *IFN-β*. (b) *IFN-λ1*, (C) *ISG-15*, and (D) *OAS1*. *GAPDH*
945 was used as house-keeping control for normalization. Data are from two independent
946 experiments (Mean ± SD). Statistical significance was estimated by two-way ANOVA
947 with Tukey's multiple comparisons test. ns: non-significant, * P<0.05, ** P<0.01, ***
948 P<0.001, **** P<0.0001.

949
950 **Figure 5: Omicron variant has milder effect on epithelial junctions.** Calu-3 cells
951 were grown on transwell inserts under air-liquid interface (ALI) conditions. Cells were
952 infected with Delta and Omicron variants at 0.3 MOI. (A) Graph indicates TEER values
953 relative to mock infection after infection at indicated time points from two independent
954 experiments. (Mean and error with range). Statistical significance was estimated by two-
955 way ANOVA with Tukey's multiple comparisons test. (B) Viral titers were measured in
956 supernatants by focus-forming units. Error bars represent (Mean ± SD) (C) At 36 h pi,
957 cells were fixed and stained with occludin, β-catenin and SARS-CoV-2 nucleocapsid
958 antibody followed by Alexa Fluor dye-conjugated secondary antibodies for visualization.
959 Nuclei were stained with DAPI. Images were captured at 100X magnification. Images
960 were analyzed using cellSens software and Z-projection images with maximum intensity
961 are shown in the figure. Scale bar is 10 μM. ns: non-significant, **** P<0.0001.

962
963 **Figure 6: Omicron infection induces cross-protective antibodies:** Calu-3 cells were
964 infected with BA.1 and BA.2 sub-lineages of the Omicron variant at 0.3 MOI. Cells were
965 collected at indicated time points and RNA was isolated. (A) SARS-CoV-2 N sub-

966 genomic copy numbers were estimated using RT-qPCR. *RNase P* was used as a
967 housekeeping control. (B) Viral titers were measured in supernatants by plaque assay.
968 Error bars represent geometric mean value with 95% CI (C) Binding antibodies to
969 nucleocapsid (N) and (D) RBD were estimated by quantitative ELISA for the three time-
970 points post-vaccination as indicated (n=15). (E) Neutralizing antibody titers to Delta
971 variant and (F) Omicron variant was determined in the same samples by FRNT assay.
972 (G) Neutralizing antibody titers to the BA.1 and BA.2 sub-lineages were determined in
973 samples from participants that were RT-PCR positive during the ongoing Omicron-
974 induced surge in COVID-19 cases (n=19). Statistical significance was estimated by
975 Kruskal-Wallis test with Dunn's multiple comparison test. ns: not significant. * P<0.05,
976 **** P<0.0001.

977

978 **Figure 7: Iron and copper salts significantly inhibits SARS-CoV-2 infection.** (A)
979 SARS-CoV-2 RdRp activity assay was performed in the presence of indicated
980 concentrations of CaCl₂/CuCl₂/FeSO₄/ZnSO₄ in the standard reaction mix containing
981 MgCl₂ and MnCl₂ and the RdRp complex (nsp7-nsp8-nsp12) of SARS-CoV-2. (B) RdRp
982 assays were performed in the presence of varying of concentrations of ZnSO₄ or (C)
983 FeSO₄ to determine the IC₅₀ values. To determine the effect of metal ions in infection,
984 Calu-3 cells were infected with indicated variants at 0.3 MOI and media containing 50
985 μM each of the indicated salts were added after virus adsorption. At 24 h pi,
986 supernatants were collected and viral titers were measured by plaque assay. The graph
987 indicates the virus titers of (D) Delta and (E) Omicron variants. Data are from two or
988 three independent experiments. Error bars represent geometric mean with 95% CI.

989 Statistical significance was estimated by Kruskal-Wallis test with Dunn's multiple
990 comparison test. ns: non-significant, * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

